Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate

S Schreiber, J Hämling, E Zehnert, S Howaldt, W Daerr, A Raedler, W Kruis

Abstract

Background—An increasing number of case reports indicate potential nephrotoxicity of 5-aminosalicylic acid (5-ASA), which shares similarities with the chemical structures of both phenacetin and acetylsalicylic acid.

Aim—In a point prevalence study the occurrence of sensitive indices indicative of early kidney malfunction was assessed in outpatients with inflammatory bowel disease.

Methods—Routine indices of kidney function (creatinine clearance, urinary protein content, pH, electrolytes, and microscopy) were investigated in 223 patients with inflammatory bowel disease as well as sensitive markers of glomerular or tubular dysfunction (microproteinuria by SDS polyacrylamide gel electrophoresis (SDS-PAGE), urinary concentrations of N-acetyl-β-D-glucosaminidase, α1-microglobulin, γ-glutamyltransferase (GGT), alkaline phosphatase (AP), and albumin). Histories of exposure to 5-ASA were assessed by questionnaire.

Results—Patients receiving high amounts of 5-ASA, both actual as well as on a lifetime basis, showed an increased prevalence of tubular proteinuria by SDS-PAGE. Raised values for urinary AP and GGT indicate proximal tubular epithelial cells as the source. All other kidney function tests were normal. Analysis of covariates indicated strong associations between disease activity and size of 5-ASA doses as well as alterations in kidney tubular function.

Conclusion—The possibility exists that high doses of 5-ASA may be associated with proximal tubular proteinuria. This point prevalence study cannot dissect the possible impact of chronic inflammation from high dose 5-ASA treatment and further prospective studies are warranted.

(Gut 1997; 40: 761–766)

Keywords: 5-aminosalicylic acid, 4-aminosalicylic acid, sulphasalazine, inflammatory bowel disease, nephrotoxicity.

Aminosalicylate compounds are widely used in both acute phase and remission maintenance treatment of inflammatory bowel disease. Considerations of long term toxicity seem important as lifetime maintenance treatment is usually recommended for ulcerative colitis.1-3 Both acetylsalicylic acid and phenacetin, which have been implicated in the occurrence of non-steroidal anti-inflammatory drug (NSAID) induced nephropathy, share structural similarities with 5-ASA.4-6 In addition, one study has indicated that 5-ASA may cause lesions to kidney tubular epithelial cells in both rats and dogs when fed in high doses.7 Studies by Mahmoud et al, which were conducted in parallel with the work presented here, indicate that patients with inflammatory bowel disease treated with 5-ASA show an increased renal leakage of albumin, as detected by sensitive techniques.8-9 These studies also suggested that microalbuminuria in patients with inflammatory bowel disease may be activity related because a correlation with increased serum tumour necrosis factor-α (TNF-α) concentrations was seen.9 No clinically relevant long term nephrotoxicity has so far been reported due to chronic sulphasalazine (SASP) or mesalazine treatment.10 The introduction of mesalazine (5-aminosalicylic acid, 5-ASA) in different pharmaceutical formulations into the treatment of patients with inflammatory bowel disease has offered the opportunity of increasing dosages much further than had been possible with sulphonamide carrier compounds such as sulphasalazine.11 14 However, systemic absorption and plasma concentrations of 5-ASA delivered from SASP were found to be lower than from equivalent doses of delayed or slow release mesalazine formulations.15-17 The potential for dose related chronic nephrotoxicity caused by long term use of mesalazines may therefore be further enhanced. We have conducted a point prevalence study using sensitive indices of renal tubular and glomerular function to assess the occurrence of altered kidney function in aminosalicylate (SASP or mesalazine) treated patients with inflammatory bowel disease.

Methods

A point prevalence study was performed with individuals selected from consecutive patients attending the Universities of Hamburg and Cologne inflammatory bowel disease outpatient clinics.

ENTRY CRITERIA

Patients with a confirmed diagnosis of Crohn’s disease or ulcerative colitis of at least six months duration were included. Salicylate
treatment had to be unchanged in the past two months preceding the study. Only patients receiving a delayed release mesalazine formulation, SASP, or no treatment were selected. Including patients on slow release mesalazine or olsalazine would have generated subgroups with small patient numbers. Concomitant treatment with corticosteroids was allowed. The maximum age was set at 60 years. Childbirth or lactation less than six months previously were exclusion criteria as well as abdominal or other major operations less than six months earlier, pre-existing renal disease (any history of renal disease dating back further than the diagnosis of inflammatory bowel disease), hypertension, diabetes mellitus, or a history of chronic ingestion of analgesics. All patients having received cytotoxic drugs (methotrexate, azathioprine), cyclosporine A, or any experimental treatment for inflammatory bowel disease within the six months preceding selection were excluded as well. Patients were also excluded who had signs of urinary tract infection by microscopy which could be confirmed by culture.

PATIENTS
A total of 223 patients out of 497 screened were entered into the study (93 with ulcerative colitis, 130 with Crohn’s disease). Reasons for exclusion of 252 patients were previous use of immunosuppressive drugs or immunomodulators (61), previous experimental treatment (49), slow release mesalazine or olsalazine treatment (43), non-compliance in collecting urine or giving plasma samples (26), unwillingness to participate in the study (19), major operations (19), age >60 (15), signs of urinary tract infections (17), history of arterial hypertension (10), chronic use of NSAID analgesics (9), diabetes mellitus (2), pregnancy/childbirth (2), or pre-existing renal disease (2). Mean duration of disease was 58.3 (range 12–132) months with a mean of 3·3 (range 1–17) acute relapses. Patients were grouped into those receiving no 5-ASA, those receiving up to 1·5 g/day, more than 1·5 but less than 3·0 g/day, and those receiving 3·0 g/day or more. In patients treated with SASP the amount of 5-ASA contained in the molecule was calculated for evaluation. No differences in disease characteristics, disease activity, or sex were seen between patients younger than 30 and those aged 30 or older. Moreover, differences in disease characteristics (location, Crohn’s disease vs ulcerative colitis, presence of extra intestinal manifestations) between different treatment groups did not reach significance.

PATIENT DATA COLLECTION
Information on previous exposure to 5-ASA containing drugs, other drugs used for the treatment of inflammatory bowel disease, and non-steroidal analgesic drugs was obtained by a questionnaire, which was administered by the physician to the patient. To improve the accuracy of these data, the patients’ medical history (prescription records) was checked whenever possible. Disease activity scores were calculated from diary cards which were filled in by the patients during the week preceding and the week after analysis of urine. Patients recorded the occurrence of specific symptoms used to calculate the Crohn’s disease activity index18 19 or the clinical colitis activity index.20 The Crohn’s disease activity index18 19 provides a calculated composite score which incorporates eight items: number of liquid or very soft stools, general wellbeing, abdominal pain, abdominal mass, relative packed red blood cell volume, body weight, extraintestinal manifestations, use of opiate receptor stimulating drugs for the control of diarrhoea. Higher scores indicate more disease activity. Patients with a score below 150 are considered to be in clinical remission. Scores above 450 reflect severely active Crohn’s disease. The clinical colitis activity index20 incorporates seven clinical items: number of stools, blood in stools, investigator’s global assessment of symptomatic state, body temperature due to colitis, abdominal pain, extraintestinal manifestations, and erythrocyte sedimentation rate. Patients with a clinical colitis activity index ≤4 are considered to be in remission.20

ANALYTICAL TECHNIQUES
All chemicals were obtained from Sigma (Munich, Germany) if not stated otherwise. Morning urine was collected and an aliquot immediately frozen. In addition, most patients collected 24 hour urine during the next day. An aliquot was taken and frozen for determination of enzyme activity. The morning urine was subjected to protein analysis by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) as described by Pesce et al.21 and Schiwa et al.22 The analysis of microproteinuria by SDS-PAGE allows the differentiation between glomerular and tubular proteinuria by protein size and pattern. The detection of significant amounts of protein with a tubular pattern, which represents proteins originating from the tubular epithelium, was considered a pathological finding.21 22 The lower sensitivity limit for urinary protein detection and analysis by SDS-PAGE was 5 mg/l, the reference range was between 7 and 56 mg/24 h (90% confidence interval). α1-Microglobulin (α1-MG) and albumin concentrations were determined by nephelometry and the activities of N-acetyl-β-D-glucosaminidase (NAG), γ-glutamyl-transferase (GGT), and alkaline phosphatase (AP) by their respective enzyme activities in 24 hour urine (Boehringer Mannheim, Mannheim, Germany). To eliminate errors in 24 hour urine sampling a gradient between enzyme activity and creatinine concentration was calculated.23 24 Normal values in healthy volunteers have been obtained by Scherberich et al.25

STATISTICS
The Mann-Whitney U test was carried out to evaluate differences between groups.26 Analysis
Results

TREATMENTS

The Table shows 5-ASA doses taken and population characteristics of the patients with inflammatory bowel disease. Forty two per cent of patients received 2.3-0 g 5-ASA/day, 8% between 1.5 g/day and 3.0 g/day, and 32.6% a maximum of 1.5 g/day. The remaining (17%) patients received no 5-ASA during the two months preceding the study. Active disease was related to higher 5-ASA dosages (p<0.0001, Table). Average duration of disease was 58.3 (range 12-132) months with an average of 3.3 (range 1-17) acute relapses. Mean duration of 5-ASA treatment was found to be 32 months.

PREVALENCE OF TUBULAR PROTEINURIA AND RAISED URINE ALKALINE PHOSPHATASE CONCENTRATIONS

Proteinuria of tubular origin detected by SDS-PAGE is a pathological finding. In our patient population an increase in prevalence of tubular proteinuria was seen with increasing daily dose of oral 5-ASA (Fig 1, p=0.0086). The parallel increased prevalence of raised urinary AP concentrations (>0.9 μmol creatinine,23 24 p=0.001), which coincided highly significantly with the detection of a tubular protein pattern (p<0.0001), indicated that the origin of urinary proteins was most likely from the proximal tubular epithelial cells (Fig 1). Eleven per cent of patients receiving no 5-ASA treatment showed a tubular proteinuria by SDS-PAGE and 5% had raised urinary AP concentrations. Disease activity, defined by the Crohn’s disease activity index or the colitis activity index, was explored as an alternative variable of either primary importance or as a confounder of altered renal function indices. The detection of tubular proteinuria by SDS-PAGE was more often seen in active disease (39 of 51 patients with a positive SDS-PAGE had active disease, p<0.0001) as well as a raised urinary AP excretion (38 active out of 44 patients, p<0.0001). In active patients with inflammatory bowel disease 43% (51/91) showed a tubular proteinuria detected by SDS-PAGE in comparison with 9.1% in inactive patients (12/132). The height of clinical disease activity score was not found to correlate with the occurrence of either a pathological SDS-PAGE result or raised urinary AP concentrations. Serum soluble interleukin-2 receptor concentrations correlated with disease activity, but no statistical relation with the occurrence of tubular proteinuria or raised urinary AP concentrations was seen (data not shown). Unfortunately, the influence of disease activity (active disease v remission) could not be statistically separated from 5-ASA dosages because of a highly significant relation between activity variables and 5-ASA doses (p<0.0001) both for patients with ulcerative colitis or Crohn’s disease. Differences between ulcerative colitis and Crohn’s disease or between different groups (disease location and extent, previous resections) did not reach statistical significance.

URINARY ALKALINE PHOSPHATASE AND γ-Glutamyltransferase ACTIVITIES

Both AP and GGT are sensitive markers of damage to the proximal tubular epithelium of the kidney. The results are expressed as marker/creatinine concentrations to standardise for differences in timing and amount of the urine collection. We found a dose dependent increase in urinary AP and GGT activities with increasing 5-ASA load with differences from normal controls reaching significance in the group of patients receiving ≥3.0 g 5-ASA/day (Fig 2). The data suggest that AP values are increased much further above normal than GGT values.

ROUTINE KIDNEY FUNCTION INDICES

Excretion rates of total protein, albumin, NAG, and α-MG were investigated. No statistical differences were seen between different
treatment groups or normal controls and patients with inflammatory bowel disease treated with 5-ASA. Creatinine clearance and pH values were very variable, and again no statistical differences were seen between normal controls and different 5-ASA treatment groups. No correlation was seen between creatinine clearance and either cumulative lifetime dose or daily dose of 5-ASA (data not shown).

**CUMULATIVE 5-ASA EXPOSURE AND TUBULAR PROTEINURIA**

Cumulative 5-ASA exposure was assessed by a questionnaire. Lifetime exposure rates to 5-ASA seemed to be related (p<0.01) to an increased prevalence of tubular membrane protein excretion (Fig 3). No significant correlation could be established between AP or GGT values and lifetime 5-ASA dosage. Moreover, no correlation was seen between cumulative dose and creatinine clearance, NAG values, total protein excretion, albumin excretion, and α1-MG values.

**Discussion**

Acute salicylate induced tubular nephrotoxicity has been seen in patients taking aspirin overdoses or large doses of sodium salicylate. It is debated whether chronic analgesic nephropathy, which is associated with consumption of large amounts of phenacetin, is associated with salicylate intake as well. Moreover, 4-aminosalicylic acid (4-ASA), a structurally related molecule which has been used for the treatment of tuberculosis over many years in high systemic doses, did not generate a chronic clinical problem with drug induced nephrotoxicity. In high doses, however, case reports indicate acute nephrotoxicity, in particular in patients with pre-existing renal damage. The evidence for 5-ASA or sulphasalazine (SASP) induced clinically relevant renal toxicity is rare. In rats and dogs, high doses of 5-ASA (far beyond those used in human treatment) were capable of inducing acute tubular and papillary necrosis when given over six to 12 months, whereas a four week treatment did not induce any changes.

In this study we have assessed sensitive indices of renal function such as classification of microproteinuria by SDS-PAGE to detect early signs of tubular dysfunction. In a point prevalence study in 223 patients with inflammatory bowel disease we found an increased prevalence of tubular membrane protein excretion, which was related to both 5-ASA dose and disease activity. The detectable excretion of tubular membrane proteins – confirmed by increased AP activity to originate most likely from proximal tubular epithelial cells – is pathological. It often precedes the clinical manifestation of chronic drug induced damage to the kidney. This study confirms the earlier work by Zehnter et al, which was conducted in fewer patients. Zehnter et al reported that a pathological SDS-PAGE showing tubular proteinuria was found only in patients treated with 5-ASA, but not in patients with inflammatory bowel disease receiving no aminosalicylates. Moreover, the authors also found raised urinary AP and GGT concentrations indicating the proximal tubular epithelium as the source of urinary protein excretion. Riley et al described a group of patients with quiescent ulcerative colitis, in whom renal dysfunction marker excretion values were above the 95th percentile for healthy volunteers, thereby raising the possibility of mild glomerular and tubular dysfunction in these patients. Recent studies have confirmed the presence of alterations of sensitive markers of renal dysfunction in patients with inflammatory bowel disease, although no relation between aminosalicylate dose, or extent or duration of disease was seen.

Moreover, abnormalities in renal function tests were seen also in non-aminosalicylate treated patients and an influence of immunological disease activity on sensitive indices of renal function was suggested. Recently, renal lesions resulting in signs of tubular dysfunction were proposed to be an extraintestinal manifestation of inflammatory bowel disease. In a point prevalence study like the one...
presented here no clear distinction between the influence of disease activity and drug treatment can be made, if increased dosage of the anti-inflammatory drug used correlates highly with disease activity. The data presented by us may therefore be indicative of either a drug induced, dose dependent or an inflammation induced, time dependent process capable of impacting on kidney function in the long term. High doses of 5-ASA may contribute to the signs of kidney tubule dysfunction seen in the study. However, 11% of non-5-ASA treated patients with inflammatory bowel disease were also excreting tubular proteins. Inflammatory mediators, including TNF-α, which are increased in inflammatory bowel disease, may play an important part in inducing tubular dysfunction.9 Our study confirms the data presented by Riley et al10 as well as others that NAG, α1-MG, creatinine clearance, albumin, and total protein excretion as well as routine kidney function indices are not raised in aminosaliclyte treated quiescent patients with inflammatory bowel disease. These markers, as well as routine kidney function indices, which have been obtained as safety indices in remission maintenance studies using 5-ASA containing drugs,11-21 may be too insensitive to detect early signs of tubular damage.52 53 Furthermore, the negative study by Riley et al10 investigated patients with quiescent ulcerative colitis. Tubular dysfunction, however, may be related to both disease activity and drug. A recent series of case reports indicate that acute renal toxicity may occur in humans with both SASP and 5-ASA treatment, in particular with delayed release mesalazine formulations. Clinical presentations have been typically with acute renal failure, acute nephritis, or nephrotic syndrome.32 Renal biopsies usually show signs of tubulointerstitial nephritis.33 34 Although most case reports indicate reversibility after cessation of the drug, in some cases permanent clinical kidney dysfunction has been reported.35 36 In all cases submitted to the pharmaceutical manufacturers37 acute renal damage was reported independent of dosage and treatment duration. Therefore, recent case reports may reflect acute allergic events rather than chronic toxicity. This hypothesis is supported by a case report in which rechallenge with both sulfasalazine and mesalazine drugs has been undertaken and in which a dose independent relapse of haematuria was found.37 The recent case reports of acute tubulointerstitial damage caused by aminosalicylates therefore most likely reflect a different pathophysiology than the findings reported in this study. The cases of acute renal failure associated with aminosalicylate therapy may describe a dose independent allergic condition, which may represent a clinical entity different from the findings reported in this study. Further prospective studies are warranted to dissect the potential influence of disease activity from 5-ASA treatment on renal tubular dysfunction. In particular the prospective evaluation of long term use of aminosalicylate drugs with different absorption kinetics (slow release mesalazine formulations (Pentasa), double molecules (olsalazine-dipentum, SASP, balsalazide), and delayed release mesalazines (Salofalk, Clofazal, Asacol)) may be of importance in dissecting the influence of a systemic load with 5-ASA from that of intestinal inflammation. Particular care should be taken in monitoring renal function indices (creatinine) in patients when further increasing long term 5-ASA dosages for treatment. However, at present no clinical data have been presented suggesting that chronic treatment with aminosalicylates is unsafe unless a hypersensitivity reaction occurs.

Parts of this work have been presented at the 95th annual meeting of the American Gastroenterological Association, 1994, New Orleans, LA, USA.

We thank Dr J Armbricht from SmithKline Beecham GmbH (Germany), C Oerns from Pharmacia AS (Sweden), Dr Tauschel from Dr Falk Pharma GmbH (Germany), and Dr M Larak from Ferring GmbH (Germany) for the helpful discussion of our findings. The contribution of detailed human toxicology and drug toxicity/side effect reports by SmithKline Beecham (Germany/United Kingdom) and Pharmacia (Sweden) is gratefully acknowledged. Parts of this work have been supported by a grant of the Deutsche Forschungsgemeinschaft (DGf Schr 512/1-2).
19 Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn’s disease activity index CDAI. *Gastroenterology* 1979; 77: 843–6.
31 Diener U, Tuczek HV, Fischer C, Maier K, Klotz U. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. *Naunyn Schmiedebergs Arch Pharmakoh* 1984; 326: 278–82.
36 Data on file reviewed by the authors: SmithKline Beecham GmbH, United Kingdom and Germany, Pharmacia A/B, Sweden, Dr Falk Pharma GmbH, Germany and Ferring GmbH, Germany.
Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.

S Schreiber, J Hämling, E Zehnter, S Howaldt, W Daerr, A Raedler and W Kruis

Gut 1997 40: 761-766
doi: 10.1136/gut.40.6.761